Why GLP-1 Costs Are a Symptom, Not the Disease
Employers are scrambling to manage GLP-1 drug costs, but the real question is why metabolic disease has become so prevalent in the workforce — and what to do about it.
Read MoreJames M. Knox writes at the intersection of human health, business strategy, and the decisions that shape how we live and work.
How Employers Can Win the Metabolic Health Crisis
A strategic guide for employers, brokers, and benefit leaders navigating the rising cost of GLP-1 medications and metabolic disease in the workforce.
A Simple Framework for Sustainable Metabolic Health
A practical, evidence-informed approach to building metabolic health habits that stick — without extreme diets or unsustainable programs.
Employers are scrambling to manage GLP-1 drug costs, but the real question is why metabolic disease has become so prevalent in the workforce — and what to do about it.
Read MoreThere's a smarter way to offer metabolic health support to employees — one that doesn't expose the medical plan to open-ended liability.
Read MoreWeight is a proxy. The Metabolic Health Index was built to track the indicators that actually predict long-term health outcomes.
Read MoreJames M. Knox has spent decades at the intersection of employee benefits, business strategy, and human health. He founded HealthDividend360 to solve a problem he kept seeing: employers caught between employee demand for modern healthcare and the financial reality of covering it.
His writing draws on real-world experience advising large employers and brokers — translating complex benefit strategy into ideas that are clear, actionable, and worth your time.
Read the Full StoryNew essays on health, business, and strategy — delivered when they're ready, not on a schedule.